Related Experiment Video

Updated: Aug 16, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Chronicles in drug discovery

V Khurdayan, M Cullell-Young

    Drug News & Perspectives
    |July 22, 2005
    PubMed

    Insights

    New research highlights IDO inhibitors for cancer immunotherapy and chemotherapy enhancement. Other studies explore gamma-secretase inhibitors for Alzheimer's, novel treatments for premature ovarian failure, selective ERbeta agonists for various diseases, and phospholipase A2 inhibitors for inflammatory conditions.

    Area of Science:

    • Oncology
    • Neurology
    • Endocrinology
    • Immunology
    • Pharmacology

    Background:

    • Indoleamine 2,3-dioxygenase (IDO) inhibitors show promise in enhancing anti-tumor immunity and chemotherapy efficacy.
    • Targeting gamma-secretase activity is a key strategy for reducing amyloid-beta production in Alzheimer's disease.
    • Novel therapeutic approaches are needed for premature ovarian failure (POF) beyond current hormone replacement therapy.
    • Selective estrogen receptor beta (ERbeta) agonists are being investigated for inflammatory and cognitive disorders.
    • Phospholipase A2 (PLA2) inhibitors are studied for their potential in treating allergies, asthma, arthritis, and atherosclerosis.

    Purpose of the Study:

    • To summarize recent advancements in IDO inhibitors for cancer treatment.
    • To review therapeutic strategies targeting gamma-secretase for Alzheimer's disease.
    • To highlight the need for new treatments for premature ovarian failure (POF).
    • To discuss the therapeutic potential of selective ERbeta agonists.
    • To present the ongoing research on specific PLA2 inhibitors for various inflammatory and cardiovascular diseases.

    Main Methods:

    • Review of recent brief reports and ongoing research findings.
    • Analysis of preclinical and clinical data on novel therapeutic agents.
    • Exploration of molecular mechanisms of action for targeted therapies.
    • Synthesis of information on drug development for specific disease areas.

    Main Results:

    • IDO inhibitors demonstrate significant antitumor effects by modulating the immune response.
    • Inhibition of gamma-secretase reduces amyloid-beta production, a target for Alzheimer's therapy.
    • Selective ERbeta agonists show potential for treating inflammatory bowel syndrome, endometriosis, and cognitive decline.
    • Specific PLA2 inhibitors are being developed as anti-inflammatory and anti-atherosclerotic agents.

    Conclusions:

    • IDO inhibitors represent a promising avenue for cancer immunotherapy and combination therapy.
    • Gamma-secretase inhibition offers a potential therapeutic strategy for Alzheimer's disease.
    • Selective ERbeta agonists hold promise for a range of estrogen-mediated conditions.
    • Targeted PLA2 inhibition presents opportunities for managing inflammatory and cardiovascular diseases.

    More Related Videos

    In Vitro Transcription Assays and Their Application in Drug Discovery09:28

    In Vitro Transcription Assays and Their Application in Drug Discovery

    Published on: September 20, 2016

    Related Concept Videos

    Drug Discovery: Overview01:26

    Drug Discovery: Overview

    Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
    Preclinical Development: Overview01:28

    Preclinical Development: Overview

    Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
    Drug Administration and Therapy Phases: Overview01:26

    Drug Administration and Therapy Phases: Overview

    Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
    The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
    The pharmacokinetic phase...
    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Structure-Activity Relationships and Drug Design01:28

    Structure-Activity Relationships and Drug Design

    Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
    SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...